Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.

British journal of haematology - 1 Aug 2020

Wilhelmson Anna S, Porse Bo T

Abstract excerpt

Recent advances in sequencing technologies have allowed for the identification of recurrent mutations in acute myeloid leukaemia (AML). The transcription factor CCAAT enhancer binding protein alpha (CEBPA) is frequently mutated in AML, and biallelic CEBPA-mutant AML was recognised as a separate disease entity in the recent World Health Organization classification. However, CEBPA mutations are co-occurring with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Proteins
Share to Clonal Evolution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Code

Share to Intracellular Signaling Peptides and Proteins

Share to Leukemia, Myeloid, Acute

Share to Precision Medicine

Share to Recurrence

Share to RNA Splicing Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 32086816
DOI: 10.1111/bjh.16534
PMCID: PMC7496298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.PMID 32086816Read ↗

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.Semantic proximity Read ↗

Complexity of CEBPA dysregulation in human acute myeloid leukemia.Semantic proximity Read ↗

Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.Semantic proximity Read ↗

Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia.Semantic proximity Read ↗

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future DirectionsSemantic proximity Read ↗

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPASemantic proximity Read ↗

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Semantic proximity Read ↗

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.Semantic proximity Read ↗

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.Semantic proximity Read ↗

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.Semantic proximity Read ↗

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.Semantic proximity Read ↗

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.